Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roman-Gomez, J
Right arrow Articles by Torres, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roman-Gomez, J
Right arrow Articles by Torres, A
Haematologica, Vol 89, Issue 1, 42-48
Copyright © 2004 by Ferrata Storti Foundation

Journal Article

The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha

J Roman-Gomez, A Jimenez-Velasco, JA Castillejo, F Cervantes, M Barrios, D Colomer, A Heiniger, and A Torres

Hematology Department, Reina Sofia Hospital, Cordoba, Spain. peperosa@teleline.es

BACKGROUND AND OBJECTIVES: Interferon-alpha (IFN-alpha) has proven useful for treating chronic myeloid leukemia (CML). However, only 7% of patients achieve a complete cytogenetic response. Although efforts to understand the molecular basis of this resistance to IFN-alpha have been made, the mechanism is still unknown. Because suppressor of cytokine signaling (SOCS) proteins are negative regulators of cytokine-induced signaling, it has been hypothesized that aberrant SOCS expression could confer resistance against cytokine therapy. DESIGN AND METHODS: In order to analyze the role of SOCS-1 in the acquisition of IFN-alpha resistance in this setting, we examined SOCS-1 mRNA expression using reverse transcription polymerase chain reaction (RT-PCR) in 75 newly diagnosed chronic phase-CML patients who received IFN-alpha therapy. RESULTS: SOCS-1 was constitutively expressed in 49 (65%) of 75 CML patients at diagnosis. Constitutive SOCS-1 expression was more frequently observed among Hasford high-risk patients (p = 0.05) and was also independently associated with a shorter median progression-free survival time (p = 0.001) and poor cytogenetic response to IFN-alpha treatment (p 0.0001). INTERPRETATION AND CONCLUSIONS: Our data indicate that constitutive expression of SOCS-1 occurs at an early stage in CML pathogenesis and probably influences the clinical behavior of the disease.


This article has been cited by other articles:


Home page
 BloodHome page
A. M. Eiring, P. Neviani, R. Santhanam, J. J. Oaks, J. S. Chang, M. Notari, W. Willis, C. Gambacorti-Passerini, S. Volinia, G. Marcucci, et al.
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis
Blood, January 15, 2008; 111(2): 816 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Zitzmann, S. Brand, E. N. De Toni, S. Baehs, B. Goke, J. Meinecke, G. Spottl, H. H.H.D. Meyer, and C. J. Auernhammer
SOCS1 Silencing Enhances Antitumor Activity of Type I IFNs by Regulating Apoptosis in Neuroendocrine Tumor Cells
Cancer Res., May 15, 2007; 67(10): 5025 - 5032.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Zimmerer, G. B. Lesinski, S. V. Kondadasula, V. I. Karpa, A. Lehman, A. RayChaudhury, B. Becknell, and W. E. Carson III
IFN-{alpha}-Induced Signal Transduction, Gene Expression, and Antitumor Activity of Immune Effector Cells Are Negatively Regulated by Suppressor of Cytokine Signaling Proteins
J. Immunol., April 15, 2007; 178(8): 4832 - 4845.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.